ThermoGenesis' stem cell harvester :
This article was originally published in Clinica
Executive Summary
Canadian regulators have given ThermoGenesis the all-clear to sell its automated system for harvesting stem cells from cord blood. The AutoXpress (AXP) device, which automates what was typically an 18-step manual process, harvests the cells in a functionally-closed processing set without requiring expensive clean rooms and labour intensive processes, said the Rancho Cordova, California firm. It also improves the recovery rates of the stem cells. The product will be marketed by its exclusive distributor, GE Healthcare.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.